Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A single institution, single arm, two-cohort feasibility trial to evaluate the combination of locoregional Y\^90 therapy with systemic atezolizumab and bevacizumab, in participants presenting with hepatocellular carcinoma (HCC) 1) within Milan Criteria (MC) with AFP ≥ 400 ng/ml as a means of bridge therapy prior to transplant, 2) beyond the Milan Criteria (MC) (within USCF DS criteria and all comers), as a means of downstaging prior to liver transplantation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony biopsją rak wątroby (HCC)
- •Dostępne próbki guza do badań laboratoryjnych
- •Zmiana pierwotna w wątrobie bez przerzutów na bazie badań obrazowych
- •Wątroba pracuje wystarczająco dobrze (skala Child-Pugh A lub B7)
- •Brak inwazji naczyń krwionośnych przez guza
- •Zgodność z kryteriami dotyczącymi wielkości i liczby zmian nowotworowych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 28, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Icahn School of Medicine at Mount Sinai
New York, United States
Trial contact
Brandy Haydel
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.